Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer
Work
Year: 2023
Type: article
Abstract: Radium-223, a targeted alpha therapy, is approved to treat bone-dominant metastatic castration-resistant prostate cancer (mCRPC), based on significantly prolonged overall survival versus placebo and a... more
Source: EClinicalMedicine
Institutions University of Washington, Fred Hutch Cancer Center, Duke University, Carolina Urologic Research Center, Tulane University +13 more
Cites: 27
Cited by: 21
Related to: 10
FWCI: 8.723
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $3,500